# US 2014/0194524 A1 · Methods for Treating Alzheimer's Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194524 A1
- Document ID: US20140194524A1
- Status: Published application
- Kind: A1
- Application number: 14/106,533
- Filed: 2013-12-13
- Published: 2014-07-10
- Earliest claimed: 2000-11-01
- Assignees: Cognition Pharmaceuticals LLC
- Applicants: Cognition Pharmaceuticals, LLC
- Inventors: Mel H. Epstein; Kjesten A. Wiig; Mark F. Bear
- Web page: https://patentgrep.com/patent/US20140194524A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/4458: only substituted in position 2, e.g. methylphenidate
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Cognitive impairments in humans with Alzheimer's disease are treated by administering a composition that includes an amphetamine compound. Memory, attention and executive function can be improved following administration of the amphetamine compound.

## Claims

### Claim 1

A method of treating a cognitive impairment in a human with Alzheimer's disease, comprising the step of administering an effective amount of a composition that includes at least about 85 mole percent l-amphetamine relative to the total amphetamine content of the composition to the human.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compositions administered to the human includes at least about 95 mole percent l-amphetamine relative to the total amphetamine content of the composition.

### Claim 3 (depends on 1)

The method of claim 1, wherein memory is improved in the human following administration of the amphetamine.

### Claim 4 (depends on 3)

The method of claim 3, wherein the improvement in memory is an improvement in at least one member selected from the group consisting of an improvement in short-term memory, long-term memory, memory consolidation, procedural memory and declarative memory.

### Claim 5 (depends on 1)

The method of claim 1, wherein attention is improved in the human following administration of the amphetamine.

### Claim 6 (depends on 1)

The method of claim 1, wherein executive function is improved in the human following administration of the amphetamine.

### Claim 7 (depends on 1)

The method of claim 1, wherein reaction time is improved in the human following administration of the amphetamine.

### Claim 8 (depends on 1)

The method of claim 1, wherein learning is improved in the human following administration of the amphetamine.

### Claim 9

A method of treating a cognitive impairment in a human with_Alzheimer's disease, comprising the step of administering an effective amount of a composition that includes at least about 85 mole percent l-amphetamine relative to the total amphetamine content of the composition to the human and wherein the l-amphetamine is administered at a dose of at least about a 2 mg and about a 60 mg dose per day.

### Claim 10

A method of treating a cognitive impairment in a human with Alzheimer's disease, comprising the step of orally administering an effective amount of a composition that includes at least about 95 mole percent l-amphetamine relative to the total amphetamine content of the composition to the human and methamphetamine content of the composition is l-amphetamine and wherein the l-amphetamine is administered at a dose of at least about a 2 mg and about a 60 mg dose per day.

### Claim 11

A method of treating a cognitive impairment in a human with Alzheimer's disease, comprising the step of orally administering an effective amount of a composition that includes at least about 95 mole percent l-amphetamine relative to the total amphetamine content of the composition to the human.